A Study to Evaluate Withdrawal Effects Following Dosing of Oxycodone/Naltrexone in Methadone-Maintained Subjects
Information source: Elite Laboratories, Inc
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Withdrawal Symptoms
Intervention: Oxycodone/Naltrexone Capsules (Drug); Oxycodone (Drug); Placebo (Drug)
Phase: Phase 3
Status: Completed
Sponsored by: Elite Laboratories, Inc Official(s) and/or principal investigator(s): Debra Kelsh, MD, Principal Investigator, Affiliation: Vince and Associates
Summary
This single-center study is a randomized, double-blind, active-controlled, multiple-dose,
parallel group study to evaluate the potential withdrawal effects, safety and tolerability,
and pharmacokinetic and pharmacodynamic effects of multiple doses of oral intact
Oxycodone/Naltrexone capsules compared to oxycodone in methadone-maintained opioid-dependent
subjects. The study will consist of a Screening Phase, an inpatient Treatment Phase
(including a methadone stabilization period, a placebo administration period, a treatment
administration period and a safety/washout period), and a Follow-up Phase.
Clinical Details
Official title: A Randomized, Double-Blind, Multiple-Dose, Parallel Group Study to Evaluate the Potential of Withdrawal Effects Following Administration of Oxycodone/Naltrexone Capsules and Oxycodone in Methadone-Maintained Opioid-Dependent Subjects
Study design: Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)
Primary outcome: Primary: Onset of Withdrawal measured by Subjective Opioid Withdrawal Scale(SOWS)Primary: Onset of Withdrawal measured by Clinician-Rated Opioid Withdrawal Scale (COWS)
Secondary outcome: Secondary: Pharmacokinetic Profile of Naltrexone and 6β-Naltrexol in Subjects receiving Oxycodone/NaltrexoneSecondary: Subjective Pharmacodynamic Effects through the use of Visual Analog Scales (VAS) Secondary: Objective Pharmacodynamic Effects through the use of Pupillometry measurements
Detailed description:
Approximately 34 methadone-maintained opioid-dependent subjects will be enrolled in the
study. All subjects will be admitted to the clinical study unit (CSU; Visit 2) for a 15-day
(with 14 overnight stays) inpatient Treatment Phase visit. Subjects will first undergo a
3-day methadone stabilization period (Days 1 to 3) in which all subjects' methadone
administration time will be gradually shifted to the time of dosing that will be used
throughout the Treatment Phase (approximately 8 am daily). Following the methadone
dosing-time stabilization period, subjects will begin a 2-day oxycodone placebo
administration period. On Day 4 and Day 5, all subjects will receive a total of 3 oxycodone
placebo doses, separated by 6 hours each, starting from approximately one hour following
methadone dose administration. Placebo will be administered in a single-blind manner.
Starting on Day 6, subjects will be randomized in a 2: 1 (Oxycodone/Naltrexone or Oxycodone)
fashion to receive one of the following treatments in a double-blinded manner:
- Oxycodone/Naltrexone, multiple oral daily dosing for 5 days
- Oxycodone, multiple oral daily dosing for 5 days Subjects will receive one of the
above-listed treatments three times daily, beginning approximately 1 hour following
methadone dosing and every 6 hours until 3 doses have been administered. Subjects will
be dosed in this manner for 5 consecutive days (Days 6 to 10). All subjects will remain
confined in the CSU for 4 days after the first of three doses of study drug is
administered on Day 10 for the safety/washout period, during which they will continue
to be assessed and monitored for withdrawal effects. Subjects will be discharged
approximately 96 hours after the first dose of study drug (oxycodone/naltrexone or
oxycodone) administered on the morning of Day 10, if medically acceptable according to
the investigator or designee. All subjects will receive daily phone calls until the
Follow-up Phase during which subjects will be asked about the presence of withdrawal
symptoms and any other adverse events (AEs).
On Days 4 to 9, safety, withdrawal, pharmacokinetic and pharmacodynamic assessments will be
performed up to 13 hours after the first of the three daily study drug doses is
administered. Following Day 10 study drug administration, assessments will be completed
until 96 hours after the first of the three daily study drug doses is administered on the
morning of Day 10.
The Follow-up Phase will be conducted approximately 10 to 14 days after the last drug
administration on Day 10 or after early withdrawal from the study and will include standard
safety assessments.
Eligibility
Minimum age: 18 Years.
Maximum age: 55 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
1. Healthy male or female subjects 18 to 55 years of age, inclusive.
2. Body mass index (BMI) within the range of 18. 0 to 35. 0 kg/m2, inclusive, and a
minimum weight of 50. 0 kg.
3. Maintained on a stable methadone regimen. Subjects must be receiving a methadone
dose of 50 to 150 mg/day at Screening, with dosage variation ≤20% for at least 14
days prior to the Screening visit and who are willing to remain on their dose at
Screening and for the duration of the study.
4. The study volunteer has been previously exposed to opioids while on methadone
maintenance without relapse occurring, or in the opinion of the methadone maintenance
program Director or Physician, is not at undue risk of relapse from participation in
the clinical study.
Exclusion Criteria:
1. History or presence of clinically significant abnormality as assessed by physical
examination, medical history, 12-lead ECG, vital signs, or laboratory values, which
in the opinion of the investigator would jeopardize the safety of the subject or the
validity of the study results.
2. Clinically significant infection/injury/illness within 1 month prior to Screening.
3. Has been diagnosed with cancer within 5 years prior to screening (excluding squamous
or basal cell carcinoma of the skin), or has an active malignancy of any type
(including squamous or basal cell carcinoma of the skin).
4. History of major mental illness that in the opinion of the investigator may affect
the ability of the subject to participate in the study. Institutionalized subjects
will not be eligible for participation.
5. Documented history of a medical condition that, in the opinion of the investigator,
would compromise the subject's ability to swallow, absorb, metabolize, or excrete
test product, including (but not limited to) intractable nausea and/or vomiting
and/or severe gastrointestinal narrowing (pathologic or iatrogenic).
6. Documented history of, or currently active, seizure disorder or history of clinically
significant head injury or syncope of unknown origin.
7. History of severe allergic reaction (including anaphylaxis) to any substance, or
previous status asthmaticus, or food allergies/intolerances/restrictions, or special
dietary needs which, in the judgment of the investigator, contraindicates the
subject's participation in the study.
8. History of allergy or hypersensitivity to oxycodone or related drugs (e. g., other
opioids) or naltrexone or related drugs (e. g., other antagonists).
9. 13. An employee of the sponsor or research site personnel directly affiliated with
this study or their immediate family member defined as a spouse, parent, child or
sibling, whether biological or legally adopted.
10. A subject who, in the opinion of the investigator or designee, is considered
unsuitable or unlikely to comply with the study protocol for any reason.
Locations and Contacts
Vince and Associates, Overland Park, Kansas 66212, United States
Additional Information
Starting date: February 2015
Last updated: March 19, 2015
|